- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: APD-356 | Belviq®
lorcaserin is an approved drug (FDA (2012))
Compound class: Synthetic organic
Comment: Lorcaserin is a selective, orally available and CNS active serotonin 2C receptor agonist that modulates appetite [2-3,5-6]. Cardiovascular safety in obese/overweight patients was reported by Bohula et al. (2018) .
Clinical formulations contain lorcaserin hydrochloride (PubChem CID 11673085).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Lorcaserin was approved by the FDA in 2012 as an adjuncttive weight-loss therapy that could be used with caloric restriction and increased physical activity in the management of chronic obesity, in patients with BMI ≥27kg/m2. In February 2019 this approval was terminated and the drug was withdrawn from the US market, because a 5 year safety trial revealed increased cancer occurrence associated with lorcaserin therapy. The increased cancer risk was considered by the FDA to outweigh the drug's clinical benefit.|
|Mechanism Of Action and Pharmacodynamic Effects|
|Lorcaserin is a selective 5-HT2C receptor agonist and acts as an anorectic, achieving weight-loss.|
For extended ADME data see the following: